Figure 9.

Adoptive transfer of SIRT^oebone marrow cells contributes to cholestatic disease progression after BDL. (A) Western blot analysis showing that bone marrow–derived cells from SIRT^oe have increased SIRT1 expression when compared with cells obtained from WT mice. (B) Fluorescence-activated cell sorting analysis of bone marrow cells isolated from WT (CD45.2) showing cell engraftment in recipient PEPC mice (CD45.1). (C) Serum levels of liver injury markers and (D) hematoxylin and eosin staining of liver sections from PEPC-Boy mice receiving bone marrow cells from WT or SIRT^oe mice analyzed at 7 days after BDL show increased liver injury in SIRT^oe/PEPC mice. Western blot analysis of whole liver lysates showing increased (E) caspase-1 cleavage and (F) IL-1β cleaved protein expression in SIRT^oe/PEPC mice 7 days after BDL. (G) Immunohistochemistry using an anti-CK19 antibody in paraffin-embedded liver sections showing enhanced ductular reaction in SIRT^oe/PEPC mice compared with WT/PEPC mice. (H) Liver fibrosis was assessed by Sirius Red staining and (I) α-smooth muscle actin immunofluorescence on liver sections from transplanted mice 7 days after BDL. Images at (D) ×4 and (G–I) ×10 are representative of n = 4–5 animals/treatment group. Values are mean ± SEM. ∗P < .05, ∗∗P < .01, ∗∗∗ P < .001 [WT/PEPC vs SIRToe/PEPC]).